Related Experiment Video
Updated: Jun 8, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Immunophenotypic predictive profiling of BRCA1-associated breast cancer
Pawel Domagala1, Tomasz Huzarski, Jan Lubinski
1Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, 70-115, Szczecin, Poland.
Virchows Archiv : an International Journal of Pathology
|October 14, 2010
Summary
BRCA1-associated cancers exhibit diverse protein expression profiles, with 92% potentially benefiting from targeted therapies like PARP-1 and EGFR inhibitors. This immunophenotypic profile aids in selecting patients for clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRCA1-associated cancers represent a distinct molecular subtype with unique therapeutic vulnerabilities.
- Comprehensive immunophenotypic profiling of predictive markers in these cancers is lacking.
- Identifying targetable proteins is crucial for advancing personalized medicine in BRCA1-mutated cancers.
Purpose of the Study:
- To comprehensively characterize the immunophenotypic profile of predictive markers in BRCA1-associated cancers.
- To assess the potential for targeted therapy based on protein expression.
- To identify patient subgroups who may benefit from specific treatment strategies.
Main Methods:
- Immunohistochemistry was employed to examine the expression of PARP-1, EGFR, c-kit, HER-2, and hormone receptors (ER/PR).
- A large cohort of BRCA1-associated breast cancers was analyzed.
- Statistical analysis was performed to correlate marker expression with clinical parameters.
Main Results:
- High expression of PARP-1 (81.9%) and EGFR (43.6%) was observed.
- Estrogen/progesterone receptor (ER/PR) expression was found in 17.9%, c-kit in 14.7%, and HER-2 in 3.6%.
- Over 62% of tumors coexpressed multiple markers, predominantly PARP-1 with EGFR or hormone receptors, suggesting broad therapeutic potential for 92% of patients.
Conclusions:
- BRCA1-associated cancers display heterogeneous expression of therapeutically relevant proteins.
- The majority of these cancers express targets amenable to specific therapies, including PARP-1 and EGFR inhibitors.
- Understanding the immunophenotypic profile is essential for patient stratification in targeted therapy clinical trials.
